Tag-Archive for ◊ fda ◊

• Friday, January 24th, 2014

Johnson & Johnson subsidiary Codman Neuro’s recall of its Trufill n-BCA liquid embolic system gets labeled as a Class I measure by the FDA. Codman Neuro, a division of Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes, said the FDA labeled its Trufill n-BCA liquid embolic system recall as Class I, the federal watchdog agency’s highest-risk classification. The […]

• Tuesday, January 21st, 2014

St. Jude Medical quietly accepts FDA premarket approval for its Cool Flex ablation catheter and ablation generator for treatment of arrhythmia. Medtech titan St. Jude Medical (NYSE:STJ) won FDA premarket approval for its Cool Flex cardiac ablation system with indication to treat irregular heart rhythms. St. Jude accepted the win quietly, with not announcements listed on its site […]

• Friday, January 17th, 2014

The FDA issues a warning letter to Philips over its late notification for the recall of a component of its InnerCool RTx temperature control device. The FDA dinged Philips (NYSE:PHG) for tardiness in its notification of the recall of a component for its InnerCool RTx body temperature control device in a warning letter sent last month. Philips […]

• Thursday, December 05th, 2013

FDA Clears TYRX Antibacterial Envelope for Use with Spinal Cord Neuromodulators MONMOUTH JUNCTION, N.J.–(BUSINESS WIRE)–TYRX, Inc. announced today that it has received U.S. Food and Drug Administration (FDA) clearance for expanded indications in marketing the AIGISRx N Antibacterial Envelope for use with spinal cord neuromodulators. This comes after the recent FDA clearance of the AIGISRx […]

• Thursday, December 05th, 2013

Dec. 3, 2013 — Certain HeartStart automated external defibrillator (AED) devices made by Philips Medical Systems, a division of Philips Healthcare, may be unable to deliver needed defibrillator shock in a cardiac emergency situation, the U.S. Food and Drug Administration said today in a new safety communication for users of these previously recalled devices. The […]

• Tuesday, November 26th, 2013

Boston Scientific Receives FDA Approval For Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent System NATICK, Mass., Nov. 25, 2013 /PRNewswire/ — Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, the company’s next-generation durable […]

• Wednesday, November 20th, 2013

AtriCure Receives FDA Approval for Investigational Study to Evaluate Stroke Prevention in Atrial Fibrillation AtriClip Left Atrial Appendage Exclusion System to be Evaluated as Alternative to Anti-Coagulation Therapy WEST CHESTER, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading developer of solutions to treat atrial fibrillation (Afib), today announced the Food and Drug Administration’s (FDA) approval to […]

• Monday, November 18th, 2013

The Food and Drug Administration on Thursday approved an implantable brain-stimulating device for patients with hard-to-treat epilepsy. The agency said it cleared Neuropace’s RNS Stimulator to reduce seizures in epilepsy patients who have not responded well to medications. The device is implanted in the skull beneath the scalp and attaches to one or two wires […]

• Saturday, November 16th, 2013

Lumenis Receives US FDA and Japanese MHLW Clearance for Array(TM) LaserLink(TM) Pattern Scanning Device for Multi-Spot Retinal Laser Treatment SAN JOSE, CA–(Marketwired – Nov 15, 2013) – Lumenis Ltd., the world’s largest medical laser company for ophthalmic, surgical and aesthetic applications, today announced that the company has received US FDA and Japanese MHLW clearance for […]

• Thursday, November 14th, 2013

Johnson & Johnson has tentatively agreed to a settlement that could reach up to $4 billion to resolve thousands of lawsuits filed by patients injured by a flawed all-metal replacement hip, said two lawyers briefed on the plan. The tentative plan, which must win court approval, represents one of the largest payouts for product liability […]